loading page

HHV8 and EBV negative primary effusion-based lymphoma: a case report of a new provisional entity and review of literature.
  • +9
  • Marta Canelo-Vilaseca,
  • Gustavo Tapia Melendo,
  • Elisa Orna,
  • Marc Sorigué,
  • Isabel Granada,
  • Azahara Palomar-Muñoz,
  • Ana Castillo,
  • Javier Grau,
  • Alba Mesa,
  • Josep-Maria Ribera,
  • Juan Manuel Sancho,
  • Jose-Tomas Navarro
Marta Canelo-Vilaseca
Hospital Germans Trias i Pujol

Corresponding Author:[email protected]

Author Profile
Gustavo Tapia Melendo
Hospital Germans Trias i Pujol
Author Profile
Elisa Orna
Hospital Germans Trias i Pujol
Author Profile
Marc Sorigué
Hospital Germans Trias i Pujol
Author Profile
Isabel Granada
Hospital Germans Trias i Pujol
Author Profile
Azahara Palomar-Muñoz
Hospital Universitario de Bellvitge
Author Profile
Ana Castillo
Hospital Germans Trias i Pujol
Author Profile
Javier Grau
Hospital Germans Trias i Pujol
Author Profile
Alba Mesa
Hospital Germans Trias i Pujol
Author Profile
Josep-Maria Ribera
Catalan Institute of Oncology-Josep Carreras Leukaemia Research Institute
Author Profile
Juan Manuel Sancho
Catalan Institute of Oncology-Josep Carreras Leukaemia Research Institute
Author Profile
Jose-Tomas Navarro
Catalan Institute of oncology-Josep Carreras Leukaemia research Institute
Author Profile

Abstract

Primary effusion lymphoma (PEL) is a rare non-Hodgkin lymphoma confined exclusively to body cavities without detectable tumor masses. The term PEL-like is an entity similar to PEL in clinical presentation but without relation to human herpesvirus 8 (HHV8). We report a case of HHV8- and EBV-negative primary effusion-based lymphoma.
19 Oct 2022Submitted to Clinical Case Reports
01 Nov 2022Submission Checks Completed
01 Nov 2022Assigned to Editor
03 Nov 2022Reviewer(s) Assigned
12 Jan 2023Review(s) Completed, Editorial Evaluation Pending
18 Jan 2023Editorial Decision: Revise Minor
27 Feb 20231st Revision Received
03 Mar 2023Submission Checks Completed
03 Mar 2023Assigned to Editor
03 Mar 2023Review(s) Completed, Editorial Evaluation Pending
12 Apr 2023Editorial Decision: Accept